{
  "id": "rna-interference",
  "title": "RNA Interference",
  "lang": "en",
  "source_lang": "en",
  "summary": "RNA interference is sequence-directed gene silencing mediated by small RNAs, with roles in cellular regulation, genome defense, experimental biology, and medicine.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "RNAi",
    "RNA-mediated interference"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/rna-interference/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/rna-interference/",
      "json": "https://aiwiki.page/zh/rna-interference.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "RNA interference (RNAi) is a group of biological processes in which small RNA molecules guide protein complexes to complementary nucleic-acid sequences and reduce their expression or activity. In its classical form, double-stranded RNA initiates the sequence-specific destruction of messenger RNA (mRNA), thereby reducing production of the corresponding protein. Related pathways repress translation or promote repressive chromatin states. RNAi is found in many eukaryotes, although its components and biological roles differ substantially among organisms.\n\nRNAi connects the regulation of gene expression with defense against viruses and mobile genetic elements. Its discovery also provided a practical means of reducing the activity of selected genes without changing their DNA sequence. Small-RNA pathways have consequently become central to functional genetics, crop biotechnology, and the development of medicines that silence disease-associated genes. Understanding RNAi requires distinguishing the production of small guide RNAs, their loading into effector proteins, and the several mechanisms by which those effectors recognize and silence targets."
    },
    {
      "heading": "Molecular scope and defining features",
      "text": "The defining principle of RNAi is that sequence information in a small RNA directs a molecular effector to a complementary target. The guide is usually about 20–30 nucleotides long, although its precise length depends on the pathway and organism. Recognition occurs through base pairing rather than through a protein surface that recognizes each target sequence independently. Changing the guide sequence can therefore redirect a shared cellular apparatus toward a different RNA.\n\nThe two principal classes associated with canonical RNAi are small interfering RNAs (siRNAs) and microRNAs (miRNAs). siRNAs generally originate from longer double-stranded RNAs and frequently direct cleavage of highly complementary targets. miRNAs usually originate from genetically encoded RNA hairpins and, especially in animals, commonly regulate targets through incomplete complementarity. Both classes act through Argonaute-family proteins, but their precursor structures, processing pathways, and patterns of target recognition differ.\n\nTerminology varies with context. In a narrow experimental sense, “RNA interference” refers to silencing initiated by introduced double-stranded RNA or siRNA. In broader molecular usage, it includes endogenous siRNA pathways and often miRNA-mediated regulation. PIWI-interacting RNAs (piRNAs) belong to a related small-RNA silencing system, but their production is generally independent of Dicer. They are therefore usually discussed alongside canonical RNAi rather than treated as an identical pathway.\n\nRNAi usually changes the abundance or utilization of RNA rather than the underlying DNA sequence. It is thus distinct from genome editing, which can introduce permanent sequence changes. RNAi-mediated reduction of expression is often called knockdown, in contrast to a genetic knockout that abolishes gene function. Knockdown can be incomplete, reversible, tissue-dependent, and strongly influenced by the persistence of the guide RNA and its target protein.\n\nNot every sequence-specific action of an RNA molecule is RNAi. Some antisense oligonucleotides recruit RNase H, alter RNA splicing, or physically block RNA interactions without involving Argonaute. Likewise, bacterial CRISPR systems use guide RNAs but possess different evolutionary origins and effector machinery. These distinctions matter when interpreting experiments and classifying therapeutics: a medicine that targets RNA is not necessarily an RNAi medicine."
    },
    {
      "heading": "Discovery and historical development",
      "text": "Several observations preceded the identification of RNAi as a unified mechanism. In 1990, experiments intended to deepen flower pigmentation in petunias instead produced flowers with reduced or variegated pigmentation. Introduction of an additional chalcone synthase gene could suppress both the introduced gene and the corresponding endogenous gene, a phenomenon called co-suppression. Related post-transcriptional silencing was investigated in plants, while “quelling” described comparable effects in the fungus Neurospora crassa. These findings suggested that additional gene copies could trigger a sequence-dependent silencing response rather than simply increase expression.\n\nThe decisive experiment was reported in 1998 by Andrew Fire, Craig Mello, and colleagues using the nematode Caenorhabditis elegans. Double-stranded RNA corresponding to a worm gene produced much stronger and more specific interference than either sense or antisense RNA alone. The response could occur at low amounts of injected RNA and extend beyond the immediately exposed cells. The work established double-stranded RNA as the effective trigger and gave the phenomenon its widely adopted name, RNA interference.\n\nIn 1999, Andrew Hamilton and David Baulcombe detected short antisense RNAs associated with post-transcriptional gene silencing in plants. Their results linked silencing to a discrete small-RNA population rather than merely to the presence of long double-stranded RNA. Biochemical studies in insect systems subsequently identified RNA-induced silencing activity, while work on the RNase III-family enzyme Dicer explained how long double-stranded precursors could be converted into short guide molecules.\n\nA major practical advance came in 2001, when Thomas Tuschl and colleagues showed that synthetic RNA duplexes about 21 nucleotides long could induce sequence-specific silencing in mammalian cells. Long double-stranded RNA often activates antiviral pathways in such cells, causing broad effects on translation and cell physiology. Short siRNAs offered a way to engage the silencing machinery while avoiding many responses associated with long double-stranded RNA. This made targeted knockdown broadly accessible in mammalian cell biology.\n\nRNAi also converged with the study of endogenous developmental regulators. The small RNA lin-4 had been characterized in C. elegans in 1993, and let-7 was described in 2000. Subsequent findings established miRNAs as a widespread class of regulatory molecules sharing central machinery with RNAi. Fire and Mello received the 2006 Nobel Prize in Physiology or Medicine for the discovery of RNA interference. The historical sequence illustrates how plant transgene experiments, fungal genetics, worm development, and biochemical studies together revealed a conserved mode of regulation."
    },
    {
      "heading": "Production and selection of small guide RNAs",
      "text": "Canonical siRNA production begins with a double-stranded RNA precursor. Such RNA may originate from a viral replication intermediate, an inverted-repeat transcript, overlapping sense and antisense transcripts, or an experimentally introduced molecule. Dicer, an enzyme of the RNase III family, cleaves the precursor into short duplexes. Its paired RNase III catalytic domains cut opposite strands, typically producing duplexes with two-nucleotide overhangs at their 3′ ends. Product length depends on the Dicer protein and associated factors; approximately 21–23 nucleotides is common, but not universal.\n\nAnimal miRNA production usually begins in the nucleus. RNA polymerase II transcribes a primary miRNA, or pri-miRNA, containing a stem-loop structure. The Microprocessor complex, comprising Drosha and its partner DGCR8 in mammals, cleaves the stem-loop from the longer transcript. The resulting precursor miRNA is commonly exported by Exportin-5 and processed by Dicer in the cytoplasm. This produces a short RNA duplex from which a functional guide can be selected.\n\nPlant miRNA processing differs in important respects. In Arabidopsis thaliana, DICER-LIKE1 performs the principal processing steps in the nucleus with accessory proteins that improve precision. Many plant small-RNA duplexes are subsequently modified by HEN1, which methylates the terminal ribose at their 3′ ends. This modification protects small RNAs against destabilizing reactions such as inappropriate tailing and trimming. Plant and animal pathways thus share an overall logic without using identical processing arrangements.\n\nAfter processing, one strand of a duplex is retained as the guide in an Argonaute protein, while the other, historically called the passenger strand, is removed. Strand selection depends partly on the relative stability of the duplex ends, the identity of terminal nucleotides, and the preferences of the Argonaute involved. The process is not absolute: both arms of some miRNA precursors produce functional guides. Their relative abundance can also vary among tissues or developmental stages.\n\nSeveral alternative pathways depart from the canonical sequence. Mirtrons are short introns whose splicing and debranching produce hairpins that bypass Drosha cleavage. Mammalian miR-451 undergoes an unusual maturation pathway involving Argonaute 2 rather than conventional Dicer cleavage. Such cases show that precursor origin alone does not define the final regulatory mechanism. The decisive event is formation of a functional guide–effector complex, although precursor processing strongly influences which guide sequences and concentrations become available."
    },
    {
      "heading": "Target recognition and silencing mechanisms",
      "text": "The central effector of canonical RNAi is an Argonaute protein carrying a guide RNA. Together with associated factors, this forms an RNA-induced silencing complex (RISC). Argonaute provides binding sites for the guide’s ends and organizes its sequence for target recognition. Structural studies have shown that the guide is not simply exposed as a free strand: its arrangement within the protein promotes initial pairing and then accommodates further pairing as a suitable target is engaged.\n\nFor many animal miRNAs, recognition begins with the seed region, usually guide positions 2–7 or 2–8 counted from the 5′ end. Complementarity to this short region can be sufficient to recruit repression, particularly when the target site occurs in an accessible part of an mRNA’s 3′ untranslated region. Additional pairing outside the seed can strengthen or alter the interaction. Because short matching sequences occur in many transcripts, one miRNA can regulate numerous genes, while one mRNA can contain sites for several different miRNAs.\n\nExtensive complementarity can support direct target cleavage, often called slicing. In human cells, AGO2 is the principal Argonaute with robust slicing activity. Cleavage generally occurs in the target strand opposite guide positions 10 and 11. The resulting RNA fragments are then degraded by cellular nucleases. Catalytic Argonautes use a metal-dependent active site within their PIWI domain, whose structure resembles that of RNase H. An appropriately loaded complex can act on multiple target molecules, making silencing more than a one-to-one sequestration reaction.\n\nWhen target pairing does not support slicing, animal miRNA complexes commonly recruit TNRC6/GW182-family proteins and downstream repression machinery. These interactions promote shortening of the mRNA poly(A) tail, removal of the 5′ cap, and degradation. They can also reduce translation before extensive RNA loss is detected. The relative contributions of translational repression and RNA destabilization depend on timing and biological context; in many steady-state mammalian measurements, reduced mRNA abundance explains a substantial part of the protein decrease.\n\nTarget engagement is not determined by sequence alone. RNA structure, nearby RNA-binding proteins, target-site location, guide concentration, and competition among transcripts influence repression. Conversely, some highly complementary targets trigger guide destabilization through target-directed miRNA degradation. These observations qualify the simple picture of a stable guide repeatedly destroying passive targets: the target can affect the lifetime of the regulator, and the same guide can produce different outcomes depending on the architecture of its interaction."
    },
    {
      "heading": "Natural functions and evolutionary distribution",
      "text": "Small-RNA silencing systems contribute both to regulation of endogenous genes and to defense against foreign or potentially harmful sequences. In plants and many invertebrates, RNAi is an important antiviral mechanism. Viral double-stranded RNA, often generated during replication, is processed into siRNAs that guide the destruction of viral RNA. Many viruses encode suppressors of RNA silencing, such as proteins that bind small-RNA duplexes or interfere with Argonaute activity. This reciprocal interaction provides evidence of sustained evolutionary conflict between hosts and viruses.\n\nIn insects, antiviral siRNA pathways are particularly well characterized in Drosophila melanogaster. Dicer-2 and Argonaute-2 have major roles in this pathway, whereas Dicer-1 and Argonaute-1 are more closely associated with miRNA regulation. These divisions are not universal rules for all animals. Mammalian antiviral defense relies heavily on innate immune pathways, including interferon signaling, and the extent of antiviral RNAi in mammals varies with cell type and experimental setting. Findings in one host therefore cannot be transferred uncritically to another.\n\nEndogenous miRNAs influence development, differentiation, and cellular homeostasis. In C. elegans, lin-4 and let-7 regulate the timing of developmental transitions by controlling target mRNAs. In mammals, miR-122 is highly enriched in the liver and participates in hepatic gene regulation, while miR-1 is associated with muscle gene networks. These are not simple switches acting on a single downstream gene. Their effects arise from combinations of targets, interaction with transcriptional programs, and changes in regulatory context.\n\nSmall-RNA pathways also constrain transposable elements, whose movement can damage genes or disrupt genome organization. In many animal germ lines, piRNA pathways perform a prominent part of this defense through cytoplasmic RNA destruction and nuclear silencing. Endogenous siRNAs contribute to transposon control in other settings. The defense of inherited genetic information is therefore distributed across several small-RNA systems, rather than assigned to a single universally conserved pathway.\n\nComparative studies indicate that RNAi-related machinery is ancient, but it has undergone extensive diversification and repeated loss. The budding yeast Saccharomyces cerevisiae, for example, lacks the canonical Dicer–Argonaute RNAi system, whereas some related yeasts retain RNAi. Organisms differ in their numbers of Dicers and Argonautes, guide lengths, amplification mechanisms, and cellular compartments of action. RNAi is accordingly best understood as an evolutionarily related collection of pathways, not as one invariant process present in every eukaryotic cell."
    },
    {
      "heading": "Nuclear silencing, amplification, and inheritance",
      "text": "Although RNAi is often depicted as cytoplasmic mRNA destruction, small RNAs can also direct changes in chromatin and transcription. These nuclear pathways recognize RNA associated with a genomic region and recruit factors that modify nearby chromatin. Sequence specificity still comes from RNA pairing, but the eventual outcome may be reduced production of new transcripts rather than accelerated removal of existing ones. This connects RNA silencing with epigenetic regulation.\n\nThe fission yeast Schizosaccharomyces pombe provides a well-studied example. siRNAs associated with the RNA-induced transcriptional silencing complex, or RITS, help identify transcripts from repetitive centromeric regions. This promotes recruitment of chromatin-modifying machinery, including the Clr4 histone methyltransferase, and formation of heterochromatin marked by methylation of histone H3 lysine 9. RNA production from the region and its subsequent recognition participate in a reinforcing cycle. Silencing therefore depends partly on transcription of the sequences that are ultimately repressed.\n\nPlants possess a distinct pathway called RNA-directed DNA methylation. In a major branch of this pathway, RNA polymerase IV and RNA-dependent RNA polymerase 2 help generate precursors that DICER-LIKE3 processes into predominantly 24-nucleotide siRNAs. These guides associate with Argonaute proteins such as AGO4 and recognize scaffold transcripts produced by RNA polymerase V. Recruitment of factors including the DRM2 methyltransferase promotes DNA methylation at corresponding loci, notably transposable elements and repetitive sequences. Noncanonical routes also contribute, so the pathway is more varied than this core sequence suggests.\n\nAmplification is another important difference among organisms. An RNA-dependent RNA polymerase can use RNA as a template to generate additional RNA, allowing a primary trigger to produce a larger population of silencing guides. In nematodes, secondary siRNAs include abundant 22G RNAs, which are 22 nucleotides long and characteristically begin with guanosine. Mammals do not possess an equivalent canonical RNAi amplification system. Consequently, the striking potency and persistence of RNAi in worms cannot be assumed for human cells.\n\nUnder particular conditions, small-RNA-associated silencing can persist across generations in nematodes and plants. Such inheritance depends on the organism, locus, exposure, and machinery involved; it does not imply that every RNAi response is heritable. Systemic spread within an organism is also distinct from inheritance between generations. In C. elegans, the SID-1 membrane protein contributes to uptake of extracellular double-stranded RNA and systemic RNAi. These phenomena illustrate separate questions: how a silencing signal is amplified, how it moves between cells, and how regulatory information survives reproduction."
    },
    {
      "heading": "Experimental gene knockdown and functional screening",
      "text": "RNAi became a major tool of functional genomics because a gene could be investigated by reducing its expression and observing the resulting phenotype. Synthetic siRNAs can be introduced into cultured cells, while longer double-stranded RNAs are effective in many invertebrate systems. In C. elegans, worms can acquire double-stranded RNA by feeding on engineered bacteria that produce it. This enabled large-scale studies linking individual genes to development, viability, metabolism, and behavior.\n\nFor longer-lasting expression, researchers commonly use short hairpin RNAs (shRNAs). A DNA vector encodes a transcript that folds into a stem-loop and is processed into an active small RNA. Such constructs can be delivered by plasmids or viral vectors and placed under constitutive or inducible regulatory control. Some designs embed the targeting sequence within a miRNA-like scaffold to exploit endogenous processing. Unlike a single administration of synthetic siRNA, continued transcription can sustain knockdown, although expression level and vector behavior introduce additional variables.\n\nRNAi screens may be performed in an arrayed format, with separate reagents in individual wells, or in pooled libraries containing many targeting constructs. In pooled screens, the abundance of associated sequence tags can be measured before and after selection. Loss or enrichment of particular constructs can reveal genes that affect survival, drug response, or another selectable property. Imaging-based arrayed screens are especially useful when the phenotype concerns cell shape, subcellular localization, or heterogeneous responses rather than simple growth.\n\nSpecificity is a central limitation. An siRNA designed to cleave one transcript can also repress other transcripts through miRNA-like seed pairing. Both strands of the duplex may contribute unintended activity. Other complications include activation of innate immune responses, saturation of endogenous processing machinery, differences in delivery, and toxicity unrelated to the intended target. A reduction in target mRNA also need not produce a prompt reduction in a long-lived protein. Measuring only one molecular endpoint can therefore misrepresent the biological perturbation.\n\nStrong evidence usually combines independent reagents targeting different sequences, measurements of both target RNA and protein where appropriate, and an orthogonal test of gene function. A particularly informative control is rescue by a version of the target gene engineered to resist the silencing reagent while retaining protein function. CRISPR knockout and CRISPR interference have replaced RNAi in some screening applications, but RNAi remains useful where partial, reversible, or transcript-selective suppression is desired. Its results describe the consequences of a particular degree and duration of depletion, not automatically the consequences of complete gene absence."
    },
    {
      "heading": "Delivery, chemical modification, and pharmacology",
      "text": "The central difficulty in therapeutic RNAi is often delivery rather than recognition of the target sequence. Unprotected RNA is vulnerable to nucleases, and its size and negative charge impede passive crossing of the cell membrane. Material entering a cell by endocytosis may remain trapped in intracellular vesicles instead of reaching the cytoplasm, where much of the RNAi machinery operates. Effective delivery must therefore address stability in body fluids, tissue distribution, cell entry, and release into the appropriate intracellular compartment.\n\nChemical modification improves the behavior of siRNA molecules. Common approaches include 2′-O-methyl and 2′-fluoro substitutions in the sugar and phosphorothioate linkages at selected backbone positions. Carefully chosen modifications can improve nuclease resistance, reduce unwanted immune recognition, and influence strand selection while preserving productive interaction with Argonaute. Modification is not unrestricted: changes at sensitive positions can impair processing, target recognition, or catalytic activity. Therapeutic designs balance these requirements rather than simply maximizing chemical protection.\n\nLipid nanoparticles provide one established delivery strategy. They package RNA within assemblies containing ionizable lipids and other lipid components. Ionizable lipids are designed to alter their charge behavior with pH, helping reconcile extracellular tolerability with intracellular delivery. After uptake, interactions with endosomal membranes can permit a fraction of the RNA cargo to escape into the cytoplasm. The liver is especially accessible to several nanoparticle formulations because of its vascular organization and uptake pathways.\n\nA second major approach attaches siRNA to N-acetylgalactosamine, commonly abbreviated GalNAc. Multivalent GalNAc binds the asialoglycoprotein receptor on hepatocytes, promoting receptor-mediated uptake. This strategy has enabled subcutaneous administration of several liver-directed RNAi medicines without a lipid nanoparticle carrier. Efficient receptor uptake does not eliminate the endosomal barrier, but the combination of targeted entry, chemical stabilization, and durable intracellular activity can produce prolonged pharmacological effects.\n\nDuration of silencing depends on more than the concentration of free drug in blood. Intracellular persistence, loading into Argonaute, target mRNA renewal, protein turnover, and cell division all contribute. A guide that remains active after circulating material has declined can continue suppressing production of its target. Conversely, long-lived proteins may decline slowly even when mRNA cleavage is efficient. These relationships explain why dosing intervals and onset of effect differ among RNAi products.\n\nDelivery beyond hepatocytes remains a major area of development. Solid tumors, skeletal muscle, the lung, and the central nervous system present different anatomical and cellular barriers. Local administration can bypass some distribution problems but does not automatically ensure access to the relevant cells. Toxicity must likewise be separated into effects of the target’s biology, unintended RNA recognition, and the delivery material itself."
    },
    {
      "heading": "RNAi medicines and clinical translation",
      "text": "RNAi medicines generally use siRNAs to reduce production of a protein whose abundance contributes to disease. The target protein need not itself be accessible to a conventional drug: its mRNA provides an alternative intervention point. In many successful applications, the liver produces the disease-associated protein, making hepatocyte-directed delivery especially useful. Clinical effectiveness nevertheless depends on a validated connection between lowering the target and improving disease outcomes, not merely on achieving molecular knockdown.\n\nIn 2018, patisiran became the first RNAi therapeutic approved by the United States Food and Drug Administration. It is delivered intravenously in a lipid nanoparticle formulation and targets transthyretin mRNA in the liver. Its initial approval concerned polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults. Transthyretin can form amyloid deposits that damage tissues; reducing its production addresses the supply of the precursor protein rather than directly removing every existing deposit. Patisiran established that systemic RNAi could be developed into an approved medicine.\n\nSeveral subsequent approvals demonstrated the utility of GalNAc-conjugated siRNAs. Givosiran, approved in the United States in 2019 for adults with acute hepatic porphyria, targets aminolevulinate synthase 1, reducing production of intermediates that accumulate in the disorder. Lumasiran, approved in 2020 for primary hyperoxaluria type 1, targets hydroxyacid oxidase 1, which encodes glycolate oxidase. This reduces glyoxylate availability and thereby lowers oxalate production. These examples show that RNAi can act on a pathway component other than the gene directly responsible for an inherited disease.\n\nInclisiran targets PCSK9 mRNA and lowers circulating low-density lipoprotein cholesterol by increasing the availability of hepatic LDL receptors. It received European Union authorization in 2020 and United States approval in 2021. Vutrisiran, another transthyretin-directed siRNA using GalNAc delivery, received its initial United States approval in 2022. Nedosiran, directed against hepatic lactate dehydrogenase A, was approved in the United States in 2023 for a defined population with primary hyperoxaluria type 1. These products differ in target, formulation, dosing, and authorized population; they are not interchangeable examples of a single treatment.\n\nClinical assessment distinguishes target reduction from patient benefit and evaluates both target-related and product-specific risks. Lowering a protein can have consequences arising from its normal physiological functions, while sequence or formulation can introduce separate adverse effects. Trials therefore assess disease-relevant clinical measures alongside pharmacodynamic markers. Development also involves manufacturing consistency, RNA integrity, impurity control, and delivery reproducibility. The approved products established RNAi as a therapeutic platform, but success with a hepatocyte target does not establish equivalent feasibility in every organ or disease."
    },
    {
      "heading": "Agricultural applications and ecological constraints",
      "text": "RNAi can modify crop traits by suppressing selected plant genes. An introduced inverted-repeat sequence can produce a hairpin RNA, generating siRNAs against a chosen transcript. One established example is the nonbrowning Arctic apple, in which suppression of polyphenol oxidase genes reduces enzymatic browning after tissue damage. Simplot’s Innate potatoes include RNAi-based suppression of genes involved in traits such as bruising and accumulation of compounds associated with acrylamide formation during high-temperature cooking. The precise traits depend on the variety and modification.\n\nPlant-mediated RNAi can also target pests or pathogens. In host-induced gene silencing, a plant produces RNA corresponding to an essential gene in an attacking organism. If the RNA reaches that organism and engages its silencing machinery, it can reduce expression of the selected target. MON 87411 maize provides a prominent insect-control example: it produces double-stranded RNA targeting the western corn rootworm Snf7 gene, alongside other insect-control traits. The target participates in cellular membrane-trafficking functions, and its disruption can impair the insect.\n\nA related approach applies double-stranded RNA externally rather than engineering the plant to produce it. Sprays and other formulations seek to protect RNA from environmental degradation and deliver it to the pest or pathogen. This can separate the RNAi agent from a permanent crop modification, but field performance depends on exposure. Sunlight, rainfall, temperature, surface nucleases, and the chemistry of the leaf or insect gut can all affect how much intact RNA reaches susceptible cells.\n\nSensitivity to environmental RNA differs sharply among organisms. Some beetles respond strongly to ingested double-stranded RNA, whereas many moths and butterflies are more difficult targets because of degradation, uptake barriers, or limited systemic spread. Fungal species likewise vary in their capacity to acquire external RNA. Successful silencing in a laboratory cell assay therefore does not establish that a field-delivered RNA will reach its target at an effective concentration. The full route from application to intracellular action must be considered.\n\nEcological specificity depends on sequence, exposure, and biological susceptibility together. A sequence selected for one pest may contain regions matching transcripts in a related nontarget species, but a match alone does not establish an adverse effect without adequate exposure and functional uptake. Risk assessment consequently examines relevant organisms and realistic exposure routes rather than relying only on the general claim that RNA is biodegradable. Resistance can also evolve through altered target sequences, reduced uptake, enhanced degradation, or changes in the silencing machinery. These constraints shape how RNAi-based crop protection is evaluated and combined with other pest-management methods."
    }
  ],
  "links": [
    "rna",
    "messenger-rna",
    "protein",
    "eukaryote",
    "gene-expression",
    "nucleotide",
    "micro-rna",
    "dna",
    "genome-editing",
    "rna-splicing",
    "enzyme",
    "cell-nucleus",
    "translation-biology",
    "virus",
    "innate-immunity",
    "interferon",
    "transposable-element",
    "chromatin",
    "epigenetics",
    "dna-methylation",
    "rna-dependent-rna-polymerase",
    "phenotype",
    "bacteria",
    "crispr",
    "cell-membrane",
    "lipid-nanoparticle"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}